A Caltech Library Service

Enhanced Efficacy of Gene Therapy Treatment for Niemann-Pick C1 Disease Using a Novel Serotype, AAV-PHP.B

Gu, Tansy and Davidson, Cristin and Gibson, Alana and Chandler, Randy and Beadle, Keith and Deverman, Ben and Ory, Daniel S. and Gradinaru, Viviana and Pavan, William J. and Venditti, Charles P. (2018) Enhanced Efficacy of Gene Therapy Treatment for Niemann-Pick C1 Disease Using a Novel Serotype, AAV-PHP.B. Molecular Therapy, 26 (5). p. 404. ISSN 1525-0016. doi:10.1016/j.ymthe.2018.05.001.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


Accessing the central nervous system (CNS) continues to present a challenge when developing therapies for the treatment of neurological diseases. Overcoming the barrier of gene transfer to brains of animals and patients from systemic circulation has been difficult. Recent advances using Cre recombination-based adeno-associated virus (AAV) targeted evolution (CREATE) has yielded a promising new serotype, AAV-PHP.B, with greater transduction than AAV9 in the adult mouse CNS after systemic delivery. Here we show systemic delivery of a therapeutic AAV-PHP.B vector outperforms the naturally occurring AAV9 in treatment of a murine model of a rare lysosomal storage disorder, Niemann-Pick C1 (NPC1) disease. Approximately 95% of patients have a mutation in NPC1 which results in either absence or a significant reduction in functional NPC1, a lysosomal transmembrane protein involved in cholesterol transport. NPC1 pathology involves lysosomal accumulation of unesterified cholesterol and other lipids. Patients typically present with neurological symptoms and visceral complications including hepatosplenomegaly. Disease progression in the null mouse model of NPC1 (Npc1-/-) is characterized by weight loss, ataxia, and early death. Results: We previously reported that systemic delivery of an AAV9 vector expressing the human NPC1 gene under transcriptional control of a ubiquitous promoter (EF1a) improved lifespan and ameliorated disease phenotype of Npc1-/- mice. Using a similar study design, we find that an otherwise identical AAV-PHP.B vector improved lifespan in Npc1-/- mice more effectively than an AAV9 vector.

Item Type:Article
Related URLs:
URLURL TypeDescription
Deverman, Ben0000-0002-6223-9303
Gradinaru, Viviana0000-0001-5868-348X
Additional Information:© 2018 American Society of Gene & Cell Therapy. Available online 9 May 2018.
Issue or Number:5
Record Number:CaltechAUTHORS:20180706-154255761
Persistent URL:
Official Citation:ASGCT 21st Annual Meeting Abstracts, Molecular Therapy, Volume 26, Issue 5, Supplement 1, 2018, Pages 1-459, ISSN 1525-0016, (
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:87623
Deposited By: Tony Diaz
Deposited On:06 Jul 2018 22:47
Last Modified:15 Nov 2021 20:50

Repository Staff Only: item control page